Medipattern's Visualize:Vascular(TM) Usage Doubles

Attention: Business/Financial Editors

The Medipattern Corporation ("Medipattern" or "the Company") (TSX VENTURE:MKI),
announced today that volume for its patented and FDA cleared
Visualize:Vascular(TM) 3D carotid rendering product doubled during the quarter
ended June 30, 2012 as compared to the previous quarter. Visualize:Vascular is
sold to the medical imaging market on a fee per use basis.


"Visualize:Vascular offers an exceptional value proposition for the vascular
market. Usage is measured through scan volume or the number of patients scanned
for evaluating their carotid arteries using Visualize:Vascular. As previously
reported scan volume for the quarter ended March 31, 2102 was 355. Scan volume
for the quarter ended June 30th was 723 which is an increase of 103% over the
prior quarter. However, the more important metric is the increase in customers
regularly using Visualize:Vascular. These customers have more than doubled and
include large multi-facility private practices which perform a large volume of
carotid procedures placing them in the over 3,000 procedures per year category.
More recent installations also include mobile ultrasound practices such as
SonoCare and MD&T of New Jersey which can average over 10,000 carotid exams per
year. Visualize:Vascular is now installed and in use in the states of North
Carolina, Pennsylvania, New Jersey, New York, and New Hampshire where
reimbursement for the procedure has been established and proves to be strongly
supported by all of the major US healthcare insurance payers including Medicare,
Blue Cross/Blue Shield, Blue Card, United Healthcare, Met Life and over 20 other
payers," stated Jeff Collins, President and CEO of Medipattern.


"While there may be other 3D software packages, Visualize:Vascular is the only
product which renders carotid residual lumen which is the pathway of blood to
the brain. Looking at the lumen in 3D gives a different perspective from the
commonly used Doppler method which measure the velocity of the blood.
Visualize:Vascular shows you the detailed shape of every restriction in the
artery and measures the change in diameter directly. Experts consider
Visualize:Vascular to be a good adjunct procedure with Doppler
"Visualize:Vascular's value proposition is strong: increased understanding of
carotid blockages which in turn leads to better patient care, and it directly
increases practice revenue while using the same ultrasound equipment that the
practice already has with no need for capital investment. Visualize:Vascular is
a win-win for patient care, medical practices, medical providers and healthcare
insurance payers," added Mr. Collins.


Carotid disease, which can lead to stroke, is linked to obesity and diabetes.
Stroke is the leading cause of morbidity and is the third leading cause of death
in the world today. The US Government Accountability Office (GAO)(1) reported
that there were more than 41 million ultrasound procedures performed in 2005;
where 75% of these procedures were cardiovascular procedures and 20% of
cardiovascular procedures or roughly 8 million were vascular procedures.
Updating this to today's volume, estimates that more than 80 million ultrasound
procedures will be performed in 2012 in the US alone, with over 55 million
cardiovascular procedures where specifically over 16 million of these are
vascular imaging; making the vascular ultrasound imaging market a $5 billion to
$8 billion a year segment within the $15 billion to $20 billion a year
cardiology ultrasound segment in the US alone. Globally, cardiovascular
ultrasound equipment is considered to be a greater than $100 billion market by
independent industry analyst Frost and Sullivan.(2) 


"As we bring on each new account there is a significant start up cycle.
Practices have to contact their referring physicians to educate them so that
they prescribe the procedure for qualifying patients. Technologists need to be
certified to scan using the proprietary Medipattern protocol and reading
physicians need to be trained to understand how to use the results. Large
practices begin to use Visualize;Vascular on a limited site / limited resource
scale and then roll-out the procedure to their other facilities and full
referring base. Our results during the past two quarters are from a mix of older
customers that are fully implemented and new customers that are still in the
roll-out phase. These sites have far greater potential which the company will
benefit from an increased scanning volume in ensuing months. Our goal is to
continue to increase volume by focusing on adding large new accounts while
continuing to deploy throughout existing accounts," concluded Mr. Collins.




(1)   United States Government Accountability Office (GAO), "Medicare       
      Ultrasound Procedures, Consideration of Payment Reforms and Technician
      Qualification Requirements" 2007 based upon 2005 data.                
(2)   Frost and Sullivan, "US Ultrasound Markets Research Report", 2004     
      #A675-50. "European Markets for Ultrasound Report, 2008", #M0D4-50.   



About the Medipattern Corporation:

Medipattern(R) is a pioneer in the development of imaging software solutions
that help medical practitioners to better understand lesions and critical
anatomy. Medipattern's technology is patented and FDA approved. Medipattern uses
its Cadenza(TM) technology to process images, finding the salient region of
interest and presenting them in 2D and 3D formats that enhance the reader's
perception. For more information, please visit the Company's website:
www.medipattern.com.


Medipattern(R) is a registered mark of The Medipattern Corporation. Cadenza(TM)
and Visualize:Vascular(TM) are trademarks of the Medipattern Corporation.
MYTRAK(R) is a registered trademark of MyTrak Health Solutions, Inc.


Forward-looking statements

This document contains forward-looking statements relating to Medipattern's
performance, operations, or business environment. These statements are based on
what we believe are reasonable assumptions given currently available information
and our understanding of Medipattern's current activities. We have tried,
whenever possible, to identify these forward-looking statements using words such
as "anticipates," "believes," "estimates," "expects," "plans," "intends,"
"potential", and similar expressions. Forward-looking statements are not
guarantees of future performance and involve risks and uncertainties that are
difficult to predict or control. A number of factors could cause actual outcomes
and results to differ materially from those expressed in forward-looking
statements. These factors include but are not limited to those set forth in the
Company's corporate filings, (posted at www.sedar.com). In addition, these
forward-looking statements relate to the date on which they are made. The
Company disclaims any intention or obligation to update or revise any
forward-looking statements for any reason. Readers should not rely on
forward-looking statements.